Financial agenda for 2024
Villepinte, 15 January 2024: Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2024.
| Publications calendar |
|
|
|
|
|
|
|
About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €753 million in revenue in 2022.
Contacts :
Guerbet
Jérôme Estampes, Chief Financial Officer + 33.1.45.91.50.00 / jerome.estampes@guerbet.com
Claire Lauvernier, Group Communication Director +33.6.79.52.11.88 / claire.lauvernier@guerbet.com
Actifin
Marianne Py, Financial Communication + 33.1.80.48.25.31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Media Relations +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com
Attachment
